白云山获苹果酸舒尼替尼上市批准

财中社
27 Nov 2024

财中社11月27日电白云山(600332/00874)发布公告,近日公司分公司白云山化学制药厂获得国家药监局签发的苹果酸舒尼替尼化学原料药上市申请批准通知书。该药物是一种新型的口服多靶点抗肿瘤药物,主要用于治疗胃肠道间质瘤、晚期肾细胞癌等。此次批准表明该原料药符合国家相关药品审评技术标准,能够进行生产销售。根据米内网数据,2023年苹果酸舒尼替尼胶囊在中国城市公立医院、县级公立医院的销售额为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10